|Bid||1.92 x 1800|
|Ask||2.08 x 1000|
|Day's Range||1.9300 - 2.0200|
|52 Week Range||1.9200 - 6.3500|
|Beta (3Y Monthly)||2.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 11, 2019 - Mar 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.50|
Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the first patient has been dosed in a Phase 1/1b clinical trial of APVO436, a novel anti-CD123 by anti-CD3 bispecific antibody based on Aptevo’s ADAPTIR™ technology, which is being developed for the treatment of patients with Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). As a novel immunotherapy, APVO436 is designed to engage the immune system to mount a targeted response against CD123-expressing hematological tumors. Cytokine release syndrome (CRS) is a significant concern with T-cell activating therapies and has been associated with severe complications in clinical trials. In preclinical studies, APVO436 induced lower levels of several key T-cell cytokines, including IFNg, IL-2, IL-6, and TNFa. Aptevo believes that the improved cytokine activation profile observed in preclinical studies of APVO436 suggest that it could offer a potential safety advantage with reduced toxicities compared to other CD123 x CD3 T-cell engagers at comparable or higher doses.
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
SEATTLE, Nov. 20, 2018 -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced.
Achieves 132% Increase in IXINITY® Quarterly Net Revenue Year-Over-Year More than Doubles Year-to-Date IXINITY Net Revenue from $8.1 Million to $16.7 Million.
Data Show That ALG.APV-527 Selectively Activates and Enhances Tumor-directed T-cell and Natural Killer (NK) Cell Responses Targets 5T4 Cancer Antigen Present on Many Types of.
Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided an update on its growth strategy for IXINITY® [Coagulation Factor IX (Recombinant)] in the United States and ex-U.S. markets. “We reached an important milestone in our IXINITY program this year as IXINITY became cash flow positive for our organization,” said Mike Adelman, Senior Vice President, Commercial Operations for Aptevo. Feedback from the Hemophilia B community suggests that a larger assay size for IXINITY would be very desirable from a patient dosing and convenience perspective and could promote broader adoption of IXINITY.
NEW YORK, Oct. 10, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
SEATTLE, Sept. 25, 2018 -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced.
Does Aptevo Therapeutics Inc. (APVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Penny stocks approaching key price levels dominate September's technical analysis buy list, telling interested traders to build watch lists and track progress while awaiting fruitful buying signals or reversals that break bullish patterns. First, establish the price level that is likely to attract strong buying interest. Second, look for the price level that is likely to attract strong selling interest.
LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Arrowhead Pharma, Inc. (NASDAQ: ARWR), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ARWR as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it presented new preclinical data on its expanding pipeline of RNA interference (RNAi) therapeutics for cardiometabolic diseases, including ARO-ANG3 and ARO-APOC3 at the Vascular Discovery: From Genes to Medicine– Scientific Sessions 2018, San Francisco, May 10-12, 2018, a symposium organized by the American Heart Association. Arrowhead intends to file clinical trial applications (CTA) for ARO-ANG3 and ARO-APOC3 before the end of 2018.